Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Lymphoma, B-Cell 1Advanced Non-small Cell Lung Cancer 1

Interventions

Cyclophosphamide 16fludarabine 12Rituximab 4Antigens, CD19 4Lenalidomide 3Immunotherapy, Adoptive 3Etoposide 3orelabrutinib 2Nivolumab 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Methotrexate 2zanubrutinib 1relmacabtagene autoleucel 1prednylidene 1obinutuzumab 1merphos 1ixazomib 1gemcitabine-oxaliplatin regimen 1fludarabine phosphate 1entecavir 1eltrombopag 1deltacortene 1abivertinib 1Vincristine 1Transplantation, Autologous 1Tenofovir 1Prednisone 1Pentostatin 1Melphalan 1Interleukin-7 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Lymphoma, B-Cell × abivertinib × Clear all
NCT03060850 2019-02-01

A Phase I Study of AC0010 in Patients With CLL/ SLL, MCL, DLBCL and Other NHL

Hangzhou ACEA Pharmaceutical Research Co., Ltd.

Phase 1 Unknown
184 enrolled
Lymphoid

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡